Full Text View
Tabular View
No Study Results Posted
Related Studies
Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients
This study has been completed.
Study NCT01515657   Information provided by PLx Pharma

First Received on January 13, 2012.   Last Updated on June 29, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Diabetes Mellitus, Type 2
Additional conditions recognized in this trial
Diabetes Mellitus
More general conditions related to this trial
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Interventions listed in this trial
PL2200 Aspirin Capsules
Immediate-Release Aspirin Tablets
Enteric-coated aspirin caplets
Additional drug interventions recognized in this trial
Aspirin
More general drug interventions related to this trial
Analgesics
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antipyretics
Antirheumatic Agents
Cardiovascular Agents
Central Nervous System Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Fibrin Modulating Agents
Fibrinolytic Agents
Hematologic Agents
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Platelet Aggregation Inhibitors
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
PLx Pharma


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services